Masafumi Ikeda

51PUBLICATIONS
328CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosisMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (51)

|Sep 26, 2026
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy.

|Sep 23, 2026
Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer.

|Sep 08, 2026
Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102.

|Aug 13, 2026
Clinical and LAT1 Biomarker Correlates of Clinical Benefit from Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer: A Post Hoc Analysis.

|Jun 12, 2026
Clinical Implications of Polyploid Giant Cancer Cells in Solid Tumors: Biology, Diagnosis, and Therapeutic Considerations.

|Mar 20, 2026
Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer.

Tomonao Taira, Tomoyuki Satake, Go Igarashi

Pageof 9

Frequent Collaborators

11 joint publications

Makoto Ueno

10 joint publications

Junji Furuse

8 joint publications

Takayuki Yoshino

7 joint publications

Naohiro Okano